date:Dec 18, 2013
study team managed to conduct a study of this size in vulnerable infants in neonatal intensive care units.
The study tested Chr. Hansens probiotic strains Bifidobacterium lactis BB-12,Streptococcus thermophilus TH-4 and Bifidobacterium infantis BB-02, in a randomised, double-blind, placebo-controlled, multicentre study. It found that risk was reduced by more than 50%.
The study findings were significant and truly encouraging, according to Chr. Hansen. Babies that received the probiotic mixture